pharmaphorum

SEPTEMBER 23, 2021

Development of the shot eventually fell behind mRNA rivals from BioNTech and Moderna, and Imperial eventually pivoted its efforts to development of possible boosters directed at emerging variants based on its self-assembling RNA (saRNA) platform. billion takeover of Translate Bio and $470 million acquisition of Tidal Therapeutics.

RNA 52

RNA Immune Response Vaccination Vaccine 52

pharmaphorum

JULY 7, 2022

The headline readout was from Cohort 1 of its ENDEAVOR trial – in 20 subjects aged four to seven – which showed a significant improvement compared to controls at one year on the North Star Ambulatory Assessment (NSAA) scale compared to a matched control group.

Gene Therapy 58

Gene Therapy Gene Protein Trials 58

pharmaphorum

JUNE 2, 2021

This sudden increase is due to reports of rare blood clots in recipients of the COVID-19 vaccines developed by AstraZeneca and more recently Johnson & Johnson. risk of developing blood clots with the contraceptive pill, with the ~0.0003% risk of blood clots with the AstraZeneca vaccine. Author Bio. HCPs compared the ~0.1%

Vaccination 105

Vaccination Vaccine Development Medicine 105

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

DECEMBER 26, 2023

Neuroscience was also a key area for the year for the audience, with a number of ground-breaking developments, including a new potential treatment for schizophrenia and positive results for psychedelics as an antidepressant. Variant of the month, EG.5 5 or ‘Eris’ was found in more than 50 countries.

Development 64

Development Clinical Trials Clinical Trials Drugs 64

pharmaphorum

OCTOBER 1, 2020

The 3 rd CAR-T approval recently hit the headlines for Kite Pharma in mantle cell lymphoma. Due to this clear clinical and commercial success, the oncology field has become saturated with companies with the hope to develop a cure… but are you aware of the new CAR-T movement beyond oncology?

Business Development 52

Business Development Medicine Development Production 52

pharmaphorum

FEBRUARY 16, 2021

But it’s the appointment of Slaoui as chief scientific advisor that’s attracting headlines, with an R&D approach that looks to be inspired by his time in charge of research at GlaxoSmithKline. Centessa has a similar approach, with each biotech working almost autonomously on a project already validated and ready for further development.

Life Science 58

Life Science Vaccination Vaccine Medicine 58